Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action

Cell Death and Differentiation

Volumn 18, Issue 6, 2011, Pages 959-973

  Lorente, M ^a   Torres, S ^a   Salazar, M ^a,b   Carracedo, A ^a,f   Hernandez Tiedra S ^a   Rodriguez Fornes F ^a   Garcia Taboada E ^a   Melendez B ^c   Mollejo, M ^c   Campos Martin Y ^c   Lakatosh, S A ^d   Barcia, J ^e   Guzman M ^a,b   Velasco, G ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f CIC BIOGUNE   (Spain)

Author keywords

ALK; autophagy; DNA arrays; Midkine; tumor xenografts

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CANNABINOID; MIDKINE; TETRAHYDROCANNABINOL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; DNA MICROARRAY; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SILENCING; GENETIC ANALYSIS; GLIOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; UPREGULATION;

ANALGESICS, NON-NARCOTIC; ANIMALS; CANNABINOIDS; CELL LINE, TUMOR; CYTOKINES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; NEOPLASM PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TETRAHYDROCANNABINOL;

ANIMALIA; CANNABIS SATIVA;

EID: 79955865808     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.170     Document Type: Article

References (40)

1. Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 2006; 60: 181-193. (Pubitemid 44709618)
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. (Pubitemid 47103521)
3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
4. Purow B, Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol 2009; 5: 419-426.
5. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010; 10: 319-331.
6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202. (Pubitemid 34575709)
7. Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007; 28: 39-45. (Pubitemid 46038536)
8. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3: 745-755. (Pubitemid 37328813)
9. Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, Giroux V et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006; 9: 301-312.
10. Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6: 313-319. (Pubitemid 30148624)
11. Velasco G, Carracedo A, Blazquez C, Lorente M, Aguado T, Haro A et al. Cannabinoids and gliomas. Mol Neurobiol 2007; 36: 60-67. (Pubitemid 351360351)
12. Guzman M, Duarte MJ, Blazquez C, Ravina J, Rosa MC, Galve-Roperh I et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006; 95: 197-203. (Pubitemid 44050919)
13. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008; 68: 339-342. (Pubitemid 351380057)
14. Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006; 66: 6748-6755. (Pubitemid 44085633)
15. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 2009; 119: 1359-1372.
16. Kadomatsu K. The midkine family in cancer, inflammation and neural development. Nagoya J Med Sci 2005; 67: 71-82.
17. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151: 1312-1318. (Pubitemid 18095263)
18. Chen S, Bu G, Takei Y, Sakamoto K, Ikematsu S, Muramatsu T et al. Midkine and LDL-receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells. J Cell Sci 2007; 120: 4009-4015. (Pubitemid 350269406)
19. Mirkin BL, Clark S, Zheng X, Chu F, White BD, Greene M et al. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 2005; 24: 4965-4974. (Pubitemid 41129100)
20. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002; 277: 35990-35998.
21. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6: 304-312. (Pubitemid 46505881)
22. Herrera B, Carracedo A, Diez-Zaera M, Gomez del Pulgar T, Guzman M, Velasco G. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res 2006; 312: 2121-2131. (Pubitemid 43850936)
23. Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006; 66: 6615-6621. (Pubitemid 44085617)
24. Tong Y, Mentlein R, Buhl R, Hugo HH, Krause J, Mehdorn HM et al. Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. J Neurochem 2007; 100: 1097-1107. (Pubitemid 46213932)
25. Kuo AH, Stoica GE, Riegel AT, Wellstein A. Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase. Oncogene 2007; 26: 859-869.
26. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005; 280: 26039-26048. (Pubitemid 41022195)
27. Mourali J, Benard A, Lourenco FC, Monnet C, Greenland C, Moog-Lutz C et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 2006; 26: 6209-6222. (Pubitemid 44204538)
28. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345-361.
29. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-974.
30. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.
31. George RE, Sanda T, Hanna M, Frohling S, Luther II W, Zhang J et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978.
32. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-970.
33. Allouche M. ALK is a novel dependence receptor: potential implications in development and cancer. Cell Cycle 2007; 6: 1533-1538. (Pubitemid 47327936)
34. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. The J Biol Chem 2002; 277: 14153-14158. (Pubitemid 34968027)
35. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6: 569-579.
36. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010; 467: 543-549.
37. Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 2009; 45: 1117-1128.
38. Lorente M, Carracedo A, Torres S, Natali F, Egia A, Hernandez-Tiedra S et al. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia 2009; 57: 1374-1385.
39. Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 2006; 107: 864-873. (Pubitemid 44232679)
40. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003; 9: 3606-3614. (Pubitemid 37169224)